ARWRvs its industry peers
A metric-by-metric comparison of ARWR against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARWREsta | $11.9B#3 | — | 19.4x#4 | 14.4x#4 | 23258.2%#1 | 99.7%#2 | 11.9%#3 | -0.3%#3 | — | — | — | — |
| MDGL | $10.9B#4 | — | 20.7x#6 | 11.3x#3 | 432.1%#2 | 38.1%#3 | -31.3%#4 | -55.0%#5 | -52.5%#3 | — | — | — |
| PTGX | $8.7B#6 | — | 13.2x#2 | 188.6x#5 | -89.4%#5 | -147.3%#5 | -343.6%#5 | -19.9%#4 | -33.5%#2 | — | — | — |
| SMMT | $10.5B#5 | — | 16.7x#3 | — | — | -387.8%#6 | — | -171.4%#6 | — | — | — | — |
| UTHR | $21.9B#2 | 19.1x#1 | 3.7x#1 | 6.9x#1 | 10.6%#4 | 11.7%#4 | 46.9%#1 | 22.6%#2 | — | — | — | — |
| ALNY | $27.3B#1 | 35.6x#2 | 20.2x#5 | 7.4x#2 | 65.2%#3 | 212.8%#1 | 13.5%#2 | 23.2%#1 | 150.5%#1 | — | — | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-08-01.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice